Daratumumab in HLA Desensitization Prior to Transplantation

General Inclusion Criteria: * Absolute neutrophil count \> 1,500 * Total bilirubin \< 1.5x institutional upper limit normal (ULN) * AST/ALT \< 2. 5 - 3x ULN (Options for patients with liver dysfunction may be available) * Creatinine clearance \> 20 ml/min Specific Inclusion Criteria \[HLA Desensitization Group\] * Calculated PRA (cPRA) greater than 50%. * Currently actively listed for heart or combined heart and kidney transplantation. * Negative pregnancy test (if woman of childbearing potential) If able to become pregnant or father a child, agreement to use one of the birth control methods described in this protocol * Able to provide informed consent General Exclusion Criteria: * Prior or current exposure to any of the following: daratumumab or other anti-CD-38 therapies, exposure to an investigational drug (including investigational vaccine) or invasive investigational medical device for any indication within 4 weeks or 5 pharmacokinetic half-lives, whichever is longer. * Chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) \< 50% of predicted normal. Note that FEV1 testing is required for participants suspected of having COPD and participants must be excluded if FEV1 is \< 50% of predicted normal. * Moderate or severe persistent asthma within the past 2 years, or uncontrolled asthma of any classification. Note that participants who currently have controlled intermittent asthma or controlled mild persistent asthma are allowed…